Multimorbidity Healthcare Expenditure in Belgium: A Four-Year Analysis (COMORB study)

Abstract

Abstract Background The complex management of health needs in multimorbid patients, alongside limited cost data, presents challenges in developing cost-effective patient-care pathways. We estimated the costs of managing 171 dyads and 969 triads in Belgium, taking into account the influence of morbidity interactions on costs. Methods We followed a retrospective longitudinal study design, using the linked Belgian Health Interview Survey 2018 and the administrative claim database 2017–2020 hosted by the Intermutualistic Agency. We included people aged 15 and older, who had complete profiles (N = 9,753). Applying a system costing perspective, average annual direct cost per person per dyad/triad was presented in 2022 Euro and comprised mainly of direct medical costs. We developed mixed models to analyze the impact of single chronic conditions, dyads, and triads on healthcare costs, considering two/three-way interactions within dyads/triads, key cost determinants, and clustering at the household level. Results People with multimorbidity constituted nearly half of the study population and their total healthcare cost constituted around three-quarters of the healthcare cost of the study population. The most common dyad, Arthropathies + Dorsopathies, with 14% prevalence rate, accounted for 11% of the total national health expenditure. The most frequent triad, Arthropathies + Dorsopathies + Hypertension, with 5% prevalence rate, contributed 5%. The average annual direct costs per person for dyads and triads were €3,515 (95%CI:3,093 − 3,937) and €4,592 (95%CI:3,920-5,264), respectively. Dyads and triads associated with cancer, diabetes, chronic fatigue, and genitourinary problems incurred the highest costs. In most cases, the cost associated with multimorbidity was lower or not substantially different from the combined cost of the same conditions observed in separate patients. Conclusion Prevalent morbidity combinations, rather than high-cost ones, made a greater contribution to total national health expenditure. Our study contributes to the sparse evidence on this topic globally and in Europe, with the aim of improving cost-effective care for patients with diverse needs.